BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11283141)

  • 21. Comparison of short-course versus long-course whole-brain radiotherapy in the treatment of brain metastases.
    Rades D; Bohlen G; Dunst J; Lohynska R; Veninga T; Stalpers L; Schild SE; Dahm-Daphi J
    Strahlenther Onkol; 2008 Jan; 184(1):30-5. PubMed ID: 18188520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
    Forouzannia A; Richards GM; Khuntia D; Mehta MP
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):785-94. PubMed ID: 17555388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results.
    Kereiakes DJ; Szyniszewski AM; Wahr D; Herrmann HC; Simon DI; Rogers C; Kramer P; Shear W; Yeung AC; Shunk KA; Chou TM; Popma J; Fitzgerald P; Carroll TE; Forer D; Adelman DC
    Circulation; 2003 Sep; 108(11):1310-5. PubMed ID: 12939212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose?
    Rades D; Heisterkamp C; Schild SE
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):398-403. PubMed ID: 20488627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A boost in addition to whole-brain radiotherapy improves patient outcome after resection of 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.
    Rades D; Pluemer A; Veninga T; Dunst J; Schild SE
    Cancer; 2007 Oct; 110(7):1551-9. PubMed ID: 17654659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
    Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
    Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of simultaneous in-field boost with helical tomotherapy for patients with one to three brain metastases.
    Rodrigues G; Yartsev S; Yaremko B; Perera F; Dar AR; Hammond A; Lock M; Yu E; Ash R; Caudrelier JM; Khuntia D; Bailey L; Bauman G
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1128-33. PubMed ID: 20675078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
    Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
    J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
    Shaw E; Scott C; Suh J; Kadish S; Stea B; Hackman J; Pearlman A; Murray K; Gaspar L; Mehta M; Curran W; Gerber M
    J Clin Oncol; 2003 Jun; 21(12):2364-71. PubMed ID: 12805339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
    Lind JS; Lagerwaard FJ; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1391-6. PubMed ID: 19289264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose escalation of whole-brain radiotherapy for brain metastases from melanoma.
    Rades D; Heisterkamp C; Huttenlocher S; Bohlen G; Dunst J; Haatanen T; Schild SE
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):537-41. PubMed ID: 19733017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life.
    Addeo R; Caraglia M; Faiola V; Capasso E; Vincenzi B; Montella L; Guarrasi R; Caserta L; Del Prete S
    BMC Cancer; 2007 Jan; 7():18. PubMed ID: 17254350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study.
    Buchsbaum JC; Suh JH; Lee SY; Chidel MA; Greskovich JF; Barnett GH
    Cancer; 2002 Apr; 94(8):2265-72. PubMed ID: 12001126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motexafin gadolinium in the treatment of brain metastases.
    Richards GM; Mehta MP
    Expert Opin Pharmacother; 2007 Feb; 8(3):351-9. PubMed ID: 17266469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motexafin gadolinium: a possible new radiosensitiser.
    Rodrigus P
    Expert Opin Investig Drugs; 2003 Jul; 12(7):1205-10. PubMed ID: 12831354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recursive partitioning analysis (RPA) class does not predict survival in patients with four or more brain metastases.
    Nieder C; Andratschke N; Grosu AL; Molls M
    Strahlenther Onkol; 2003 Jan; 179(1):16-20. PubMed ID: 12540980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole brain radiotherapy for brain metastases from breast cancer: estimation of survival using two stratification systems.
    Viani GA; Castilho MS; Salvajoli JV; Pellizzon AC; Novaes PE; GuimarĂ£es FS; Conte MA; Fogaroli RC
    BMC Cancer; 2007 Mar; 7():53. PubMed ID: 17386108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients.
    Rades D; Lohynska R; Veninga T; Stalpers LJ; Schild SE
    Cancer; 2007 Dec; 110(11):2587-92. PubMed ID: 17893909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer.
    Thomas SR; Khuntia D
    Int J Nanomedicine; 2007; 2(1):79-87. PubMed ID: 17722515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.